SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
U.S. President Donald Trump listens as Moncef Slaoui, the former head of GlaxoSmithKlines vaccines division, speaks about coronavirus vaccine development in the Rose Garden of the White House on May 15, 2020 in Washington, DC. Dubbed "Operation Warp Speed," the Trump administration is announcing plans for an all-out effort to produce and distribute a coronavirus vaccine by the end of 2020. (Photo: Drew Angerer/Getty Images)
Ethics Complaint Filed to Force Trump's Covid-19 Vaccine Czar--a Former Pharma Exec--to Submit to Ethics Rules
"Trump has put a pharmaceutical executive in charge of handing out the government contracts for coronavirus vaccine development. How could this possibly go wrong?"
May 28, 2020
A pair of consumer watchdog groups on Thursday filed a formal federal ethics complaint stating that President Donald Trump's so-called "Vaccine Czar"--a former pharmaceutical executive with deep personal investments in the industry--should be forced to submit to the same conflict of interest and financial disclosure rules as other government officials charged with overseeing large sums of taxpayer money, especially as he stands to personally profit from his duties.
"Slaoui's blatant ties to Big Pharma, including the very drug corporations he's funneling money to, should make even the Trump administration blush."
--Margarida Jorge, Lower Drug Prices Now
The complaint--filed by Public Citizen and Lower Drug Prices Now filed with the inspector general of the U.S. Department of Health and Human Services (HHS) and the Office of Government Ethics (OGE)--targets Moncef Slaoui, selected by Trump earlier this month to help lead what the White House dubbed "Operation Warp Speed," a task force charged with leading the government's effort to find treatments and a possible vaccine to the Covid-19 virus.
A former executive at pharma giant GlaxoSmithKline, Slaoui has refused to divest his stock holdings in the company--"This is my retirement," he said earlier this month--and Trump has labeled him as a private contractor instead of a government employee. The complaint, however, says Slaoui--given that he will be in charge of awarding contracts and directing large sums of public resources--should be labeled as a special government employee (SGE) which would then require stricter ethical standards and disclosure requirements.
According to the complaint:
The contractual arrangement that regards Slaoui as merely a private contractor appears unwarranted and designed primarily to allow Slaoui to maintain an extensive web of conflicting financial interests without the need to divest of, recuse from or disclose those conflicting interests. This would otherwise constitute a violation of federal ethics laws. The arrangement provides Slaoui with the opportunity to enrich himself, his colleagues and his employers, and calls into question the integrity of critically-important official actions that will be taken under the Warp Speed program.
"Slaoui is a venture capitalist in the pharmaceutical industry who personally stands to make a fortune from determining winners and losers in the race to develop a vaccine, yet he is exempt from ethics laws that prevent self-dealing," said Craig Holman, government affairs lobbyist for Public Citizen. "It is deeply troubling that Trump has appointed a pharmaceutical executive and private contractor to help award these massive and critical government contracts."
In most similar situations, explained Public Citizen in a statement, "people who are appointed to lead government programs or instruct other government employees, and who are supervised by senior government officials, are classified as government employees subject to conflict of interest laws and disclosure requirements. This is to ensure that employees or agents working on the government's behalf serve the public interest."
"Slaoui's blatant ties to Big Pharma, including the very drug corporations he's funneling money to, should make even the Trump administration blush," said Margarida Jorge, campaign director of Lower Drug Prices Now.
"The Trump administration continues to put corporate cronyism and profits for pharmaceutical executives ahead of public health," Jorge added. "To guarantee affordable medicines for COVID-19, Congress must block monopoly control over prices and pass safeguards that prevent corporations and shareholders from profiteering off the pandemic."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
A pair of consumer watchdog groups on Thursday filed a formal federal ethics complaint stating that President Donald Trump's so-called "Vaccine Czar"--a former pharmaceutical executive with deep personal investments in the industry--should be forced to submit to the same conflict of interest and financial disclosure rules as other government officials charged with overseeing large sums of taxpayer money, especially as he stands to personally profit from his duties.
"Slaoui's blatant ties to Big Pharma, including the very drug corporations he's funneling money to, should make even the Trump administration blush."
--Margarida Jorge, Lower Drug Prices Now
The complaint--filed by Public Citizen and Lower Drug Prices Now filed with the inspector general of the U.S. Department of Health and Human Services (HHS) and the Office of Government Ethics (OGE)--targets Moncef Slaoui, selected by Trump earlier this month to help lead what the White House dubbed "Operation Warp Speed," a task force charged with leading the government's effort to find treatments and a possible vaccine to the Covid-19 virus.
A former executive at pharma giant GlaxoSmithKline, Slaoui has refused to divest his stock holdings in the company--"This is my retirement," he said earlier this month--and Trump has labeled him as a private contractor instead of a government employee. The complaint, however, says Slaoui--given that he will be in charge of awarding contracts and directing large sums of public resources--should be labeled as a special government employee (SGE) which would then require stricter ethical standards and disclosure requirements.
According to the complaint:
The contractual arrangement that regards Slaoui as merely a private contractor appears unwarranted and designed primarily to allow Slaoui to maintain an extensive web of conflicting financial interests without the need to divest of, recuse from or disclose those conflicting interests. This would otherwise constitute a violation of federal ethics laws. The arrangement provides Slaoui with the opportunity to enrich himself, his colleagues and his employers, and calls into question the integrity of critically-important official actions that will be taken under the Warp Speed program.
"Slaoui is a venture capitalist in the pharmaceutical industry who personally stands to make a fortune from determining winners and losers in the race to develop a vaccine, yet he is exempt from ethics laws that prevent self-dealing," said Craig Holman, government affairs lobbyist for Public Citizen. "It is deeply troubling that Trump has appointed a pharmaceutical executive and private contractor to help award these massive and critical government contracts."
In most similar situations, explained Public Citizen in a statement, "people who are appointed to lead government programs or instruct other government employees, and who are supervised by senior government officials, are classified as government employees subject to conflict of interest laws and disclosure requirements. This is to ensure that employees or agents working on the government's behalf serve the public interest."
"Slaoui's blatant ties to Big Pharma, including the very drug corporations he's funneling money to, should make even the Trump administration blush," said Margarida Jorge, campaign director of Lower Drug Prices Now.
"The Trump administration continues to put corporate cronyism and profits for pharmaceutical executives ahead of public health," Jorge added. "To guarantee affordable medicines for COVID-19, Congress must block monopoly control over prices and pass safeguards that prevent corporations and shareholders from profiteering off the pandemic."
A pair of consumer watchdog groups on Thursday filed a formal federal ethics complaint stating that President Donald Trump's so-called "Vaccine Czar"--a former pharmaceutical executive with deep personal investments in the industry--should be forced to submit to the same conflict of interest and financial disclosure rules as other government officials charged with overseeing large sums of taxpayer money, especially as he stands to personally profit from his duties.
"Slaoui's blatant ties to Big Pharma, including the very drug corporations he's funneling money to, should make even the Trump administration blush."
--Margarida Jorge, Lower Drug Prices Now
The complaint--filed by Public Citizen and Lower Drug Prices Now filed with the inspector general of the U.S. Department of Health and Human Services (HHS) and the Office of Government Ethics (OGE)--targets Moncef Slaoui, selected by Trump earlier this month to help lead what the White House dubbed "Operation Warp Speed," a task force charged with leading the government's effort to find treatments and a possible vaccine to the Covid-19 virus.
A former executive at pharma giant GlaxoSmithKline, Slaoui has refused to divest his stock holdings in the company--"This is my retirement," he said earlier this month--and Trump has labeled him as a private contractor instead of a government employee. The complaint, however, says Slaoui--given that he will be in charge of awarding contracts and directing large sums of public resources--should be labeled as a special government employee (SGE) which would then require stricter ethical standards and disclosure requirements.
According to the complaint:
The contractual arrangement that regards Slaoui as merely a private contractor appears unwarranted and designed primarily to allow Slaoui to maintain an extensive web of conflicting financial interests without the need to divest of, recuse from or disclose those conflicting interests. This would otherwise constitute a violation of federal ethics laws. The arrangement provides Slaoui with the opportunity to enrich himself, his colleagues and his employers, and calls into question the integrity of critically-important official actions that will be taken under the Warp Speed program.
"Slaoui is a venture capitalist in the pharmaceutical industry who personally stands to make a fortune from determining winners and losers in the race to develop a vaccine, yet he is exempt from ethics laws that prevent self-dealing," said Craig Holman, government affairs lobbyist for Public Citizen. "It is deeply troubling that Trump has appointed a pharmaceutical executive and private contractor to help award these massive and critical government contracts."
In most similar situations, explained Public Citizen in a statement, "people who are appointed to lead government programs or instruct other government employees, and who are supervised by senior government officials, are classified as government employees subject to conflict of interest laws and disclosure requirements. This is to ensure that employees or agents working on the government's behalf serve the public interest."
"Slaoui's blatant ties to Big Pharma, including the very drug corporations he's funneling money to, should make even the Trump administration blush," said Margarida Jorge, campaign director of Lower Drug Prices Now.
"The Trump administration continues to put corporate cronyism and profits for pharmaceutical executives ahead of public health," Jorge added. "To guarantee affordable medicines for COVID-19, Congress must block monopoly control over prices and pass safeguards that prevent corporations and shareholders from profiteering off the pandemic."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.